Saga University Hospital

The trials here

What the 39 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis13 trials
• Crohn's disease9 trials
• Fatty liver disease (MASLD/MASH)7 trials
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 trials
• Coronary artery disease2 trials
• Haemophilia2 trials
• Liver cirrhosis2 trials
• Acute lymphoblastic leukaemia1 trial
• Glioblastoma1 trial
• High blood pressure1 trial
• Lung cancer1 trial
• Lupus (SLE)1 trial
• and 5 more

Phase

• Phase 326 trials
• Phase 210 trials
• Phase 2/32 trials
• Phase 41 trial

Status

• Recruiting16 trials
• Completed13 trials
• Active, not recruiting10 trials

Lead sponsor

• Janssen Research & Development, LLC8 trials
• Pfizer5 trials
• Eli Lilly and Company4 trials
• Hoffmann-La Roche3 trials
• Abivax S.A.2 trials
• and 14 more

Running trials

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Hirokazu Takahashi (principal investigator)

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

  Contact: Haruki Koike, MD

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

  Contact: Haruki Koike, MD

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  NCT06663332· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

  Contact: Nanae Tsuruoka (principal investigator)

• Active, not recruiting

  A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06254950· Phase 2· Takeda· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Eli Lilly and Company· Source

  Contact: Toshihiko Kakiuchi (principal investigator)

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06260163· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Recruiting

  A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  NCT05287126· Phase 2· Pfizer· Source

• Active, not recruiting

  A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT05648500· Phase 3· Viatris Innovation GmbH· Source

• Recruiting

  A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B

  NCT05611801· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Pfizer· Source

• Active, not recruiting

  An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

  NCT03950232· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03178552· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  Phase III Trial of Stage I Ovarian Cancer After Surgery

  NCT04063527· Phase 3· Japanese Gynecologic Oncology Group· Source

  Contact: Masatoshi Yokoyama

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease6 recruiting
• Ulcerative colitis4 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Haemophilia1 recruiting
• Liver cirrhosis1 recruiting
• Ovarian cancer1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting

Closed trials

• Completed

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

  NCT05784246· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Kowa Research Institute, Inc.· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Completed

  A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT04397263· Phase 3· Janssen Pharmaceutical K.K.· Source

• Completed

  Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

  NCT04102150· Phase 2· Daiichi Sankyo Co., Ltd.· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773· Phase 2· Eli Lilly and Company· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source

• Completed

  Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

  NCT02761070· Phase 3· Kyorin University· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source

• Completed

  Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease

  NCT01422421· Phase 4· Takeshi Morimoto· Source